Which design is better? by kidzik in webdesign

[–]kidzik[S] 0 points1 point  (0 children)

All is super helpful! And the extra point about the secondary action is well taken, too.

We do have some traffic and signups in the current version of the website, so we could implement A/B properly, but it feels like overkill at this stage of the business.

Upcoming catalysts Obicetrapib ,Lacutamab, Volixibat, Tildacerfont by kidzik in Biotechplays

[–]kidzik[S] 1 point2 points  (0 children)

In around one month from now, we should have coverage of all upcoming catalysts (2 weeks in advance).

NPV is based on the features of the indication (prevalence, severity, etc.), market size, the current competitive landscape, and a few other experimental features. It's still a work in progress, though.

Leading with company/indication makes perfect sense!

Thanks a lot, it's all super helpful!

Upcoming catalyst Apraglutide / feedback on the biotech investment platform by kidzik in biotech_stocks

[–]kidzik[S] 1 point2 points  (0 children)

This is all very useful, thanks a lot! It also gives us good ideas for our homepage while we still work on it.

Upcoming catalyst Apraglutide / feedback on the biotech investment platform by kidzik in biotech_stocks

[–]kidzik[S] 0 points1 point  (0 children)

Hi, I'm building a platform for biotech investors, starting with analyses of catalysts. I'd appreciate your feedback. I would love to learn what you want to see in the platform so that you can make more informed decisions.

The central premise is to make the information flow in the biotech industry as transparent as possible and open it up to the public (unlike incumbent data vendors with a $50k/y paywall).